Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose

2001 ◽  
Vol 38 (4) ◽  
pp. 754-760 ◽  
Author(s):  
Aftab S. Chishti ◽  
Jonathan M. Sorof ◽  
Eileen D. Brewer ◽  
Arundhati S. Kale
Keyword(s):  
Focal Segmental Glomerulosclerosis ◽  
Term Treatment ◽  
Single Daily Dose ◽  
Segmental Glomerulosclerosis ◽  
Long Term Treatment ◽  
Daily Dose

scholarly journals Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis

1995 ◽  
Vol 48 (5) ◽  
pp. 1435-1450 ◽  
Author(s):  
Wilhelm Kriz ◽  
Brunhilde Hähnel ◽  
Sigrid Rösener ◽  
Marlies Elger
Keyword(s):  
Focal Segmental Glomerulosclerosis ◽  
Term Treatment ◽  
Segmental Glomerulosclerosis ◽  
Long Term Treatment

scholarly journals Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient

2007 ◽  
Vol 22 (8) ◽  
pp. 2366-2370 ◽  
Author(s):  
M. Bodmer ◽  
P. Amico ◽  
M. J. Mihatsch ◽  
M. Haschke ◽  
O. Kummer ◽  
...  
Keyword(s):  
Focal Segmental Glomerulosclerosis ◽  
Term Treatment ◽  
Myeloma Patient ◽  
Segmental Glomerulosclerosis ◽  
Long Term Treatment

scholarly journals Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY

2018 ◽  
Vol 179 (6) ◽  
pp. 419-427 ◽  
Author(s):  
Michael Buchfelder ◽  
Aart-Jan van der Lely ◽  
Beverly M K Biller ◽  
Susan M Webb ◽  
Thierry Brue ◽  
...  
Keyword(s):  
Interim Analysis ◽  
Growth Hormone Receptor ◽  
Normal Liver ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Daily Dose ◽  
Liver Tests ◽  
Time Point

Objectives ACROSTUDY is an international, non-interventional study of acromegaly patients treated with pegvisomant (PEGV), a growth hormone receptor antagonist and has been conducted since 2004 in 15 countries to study the long-term safety and efficacy of PEGV. This report comprises the second interim analysis of 2090 patients as of May 12, 2016. Methods Descriptive analyses of safety, pituitary imaging and outcomes on PEGV treatment up to 12 years were performed. Results Prior to starting PEGV, 96% of patients had reported surgery, radiation, medical therapy or any combinations of those. At start of PEGV, 89% of patients had IGFI levels above the upper limit of normal (ULN). The percentage of patients with normal IGFI levels increased from 53% at year 1 to 73% at year 10, and the average daily dose of PEGV increased from 12.8 mg (year 1) to 18.9 mg (year 10). A total of 4832 adverse events (AEs) were reported in 1137 patients (54.4%), of which 570 were considered treatment related in 337 patients (16.1%). Serious AEs were reported in 22% of patients, of which 2.3% were considered treatment related. Locally reported MRIs showed most patients (72.2%) had no change in tumor size relative to the prior scan; 16.8% had a decrease, 6.8% an increase and 4.3% both. In patients with normal liver tests at PEGV start, an ALT or AST elevation of >3× ULN at any time point during their follow-up was reported in 3%. Conclusions This second interim analysis confirms that long-term use of PEGV is an effective and safe treatment in patients with acromegaly.

scholarly journals Methotrexate induced ventricular arrhythmia as a medication error: a case report

2019 ◽  
Vol 8 (9) ◽  
pp. 2163
Author(s):  
Shailja S. Shah ◽  
Sapna Gupta ◽  
Jasvin Vala ◽  
Supriya D. Malhotra ◽  
Pankaj Patel
Keyword(s):  
Ventricular Arrhythmia ◽  
Therapeutic Index ◽  
Term Treatment ◽  
Weekly Dose ◽  
Narrow Therapeutic Index ◽  
Patient Comprehension ◽  
Long Term Treatment ◽  
Daily Dose ◽  
Life Threatening

Methotrexate (MTX) is the most widely used drug in clinical practice for long term treatment of connective tissue disorders. As this drug has narrow therapeutic index, if it goes unmonitored can lead to life threatening complications. Herein we are describing the case of a patient who presented with ventricular arrhythmia, due to failure to execute MTX therapy in the prescribed frequency and took daily dose of MTX which was meant to be taken as a weekly dose pointing to failure of patient education or patient comprehension regarding MTX and finally succumbed due to cardiogenic shock. We concluded this causality as probable/likely category according to WHO-UMC causality categories. 

Simvastatin and pravastatin: A daily dose of 40 mg in the long-term treatment of primary hypercholesterolemia

1994 ◽  
Vol 55 (4) ◽  
pp. 446-454 ◽  
Author(s):  
C. Stefanutti ◽  
A. Vivenzio ◽  
G. Lucani ◽  
S. Di Giacomo ◽  
C. Colombo ◽  
...  
Keyword(s):  
Term Treatment ◽  
Primary Hypercholesterolemia ◽  
Long Term Treatment ◽  
Daily Dose
Sign in / Sign up

Export Citation Format

Share Document